This Week in Cardiology

GLP-1 agonists in HFpEF, DOACs for subclinical AF, renal denervation, and the matter of remaining in the profession are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Obesity and HFpEF

GLP-1 Agonists in HFpEF With Obesity: Are We There Yet? https://www.medscape.com/viewarticle/993980

Wegovy Scores HFpEF Benefits in People With Obesity https://www.medscape.com/viewarticle/995844

- Semaglutide in Obese Patients With HFpEF https://www.nejm.org/doi/full/10.1056/NEJMoa2306963

- Rationale/Protocol Paper https://doi.org/10.1016/j.jchf.2023.05.010

II. DOAC for Subclinical AF

- NOAH-AFNET 6 Rationale/Protocol https://doi.org/10.1016/j.ahj.2017.04.015

- NOAH-AFNET 6 Trial Results https://www.nejm.org/search?q=NOAH+AFNET

III. Renal Denervation

ReCor Renal Denervation System Safe, Effective: FDA Panel https://www.medscape.com/viewarticle/995741

FDA Panel Split on Efficacy of Spyral Renal Denervation https://www.medscape.com/viewarticle/995800

SPYRAL HTN-ON MED https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00455-X/fulltext

IV. Maintenance of Certification

As MOC Debate Heats Up, Cardiology Societies Weigh In https://www.medscape.com/viewarticle/moc-debate-heated-cardiology-societies-weigh-2023a1000jju

Features

Mandrola's 5 Things to Look for at the Upcoming ESC 2023

https://www.medscape.com/viewarticle/995614

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact: [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

ICD generator change, less is more in VT management, co-morbidity in HF, and SGLT2i after AF ablation are the topics discussed by John Mandrola, MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. ICD Gen Change

- Patients' Perspectives Regarding Generator Exchanges of Implantable Cardioverter Defibrillators https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.122.009827

- DEFINITE https://www.nejm.org/doi/10.1056/nejmoa033088

- SCD-HeFT https://www.nejm.org/doi/full/10.1056/nejmoa043399

- DANISH https://www.nejm.org/doi/10.1056/NEJMoa1608029

- Poole and colleagues; 11-year follow-up of SCD-HeFT https://doi.org/10.1016/j.jacc.2020.05.061

- Editorial – Howell/Stecker https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010266

II. VT Therapy

Crossed Wires: Ischemia Testing and Monomorphic VT Storm

https://www.medscape.com/viewarticle/995401

- Cleveland Clinic Study

https://doi.org/10.1016/j.jacep.2023.04.030

III. Co-Morbidity in HF

- Hospital admissions in the last year of life of patients with heart failure

https://doi.org/10.1093/ehjqcco/qcad047

- Four Horsemen of Apocalypse Lecture

http://www.louisvillelectures.org/imblog/2017/10/5/whw8sf0m1k0wi6lm6kvjsx4nxzzjg5

IV. SGLT2i After Ablation for AF

SGLT2 Inhibitors Curb AF Post-Ablation Recurrences in Diabetes

https://www.medscape.com/viewarticle/995415

- Observational Study – Abu-Qaoud et al

https://www.jacc.org/doi/full/10.1016/j.jacep.2023.06.008

- Meta-analysis SGLT2i and AF

https://www.ahajournals.org/doi/full/10.1161/JAHA.121.022222

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Observational studies, another defense of digoxin, CTO-PCI, BP measurement, and a possible revolution in cardiovascular protection are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Observational Research

Yeh; Credibility in Observational Research https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064645

Hernan; Causal Language in Observational Research https://ajph.aphapublications.org/doi/full/10.2105/AJPH.2018.304337

Wang; RCT Duplicate Initiative https://jamanetwork.com/journals/jama/fullarticle/2804067

II. Defense of Digoxin

Brophy; Beta Blockers, Digoxin, or Both https://doi.org/10.1016/j.cjca.2023.06.009

Dorian editorial https://doi.org/10.1016/j.cjca.2023.07.013

Ziff Digoxin Meta-analysis https://www.bmj.com/content/351/bmj.h4451.long

DIG trial https://www.nejm.org/doi/full/10.1056/nejm199702203360801

Davila Analysis of DIG Trial https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6801940/

Kotecha Meta-analysis of Beta Blockers https://pubmed.ncbi.nlm.nih.gov/25193873/

RATE-AF https://jamanetwork.com/journals/jama/fullarticle/2774407

III. CTO-PCI

PCI of Chronic Total Occlusions Improves Angina, Quality of Life in Trials https://www.medscape.com/viewarticle/994739

JAMA Network Open Meta-analysis

IV. BP Measurement

One Size Doesn't Fit All in Blood Pressure Measurement https://www.medscape.com/viewarticle/995216

Ishigami Blood Pressure Measurement Comparison

https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2807853

V. GLP-1 SELECT Trial

Semaglutide Cuts Cardiovascular Events in Landmark Trial

https://www.medscape.com/viewarticle/995270

SELECT Protocol Paper

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback re observational studies, surgeons' dissent from recent guidelines, aspirin for primary prevention, and fish oil are the topics discussed by John Mandrola.MD in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Heart Surgeons Dissent

Surgical Groups Push Back Against New Revascularization Guidelines

https://www.medscape.com/viewarticle/966153

New Revascularization Guidelines: Key Points and Navigating Controversies

https://www.medscape.com/viewarticle/972014

- AHA Guidelines - https://doi.org/10.1161/CIR.0000000000001168

- AATS statement 2023 https://doi.org/10.1016/j.jtcvs.2023.03.001

- Yusef and colleagues 1994 Meta-analysis - https://doi.org/10.1016/S0140-6736(94)91963-1

- 10-year SYNTAXES https://doi.org/10.1016/S0140-6736(19)31997-X

- Surgeons' argument 2021 https://doi.org/10.1016/j.athoracsur.2021.12.003

- FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299

- Gaudino Meta-analysis of Medical Therapy vs CABG https://doi.org/10.1016/j.jtcvs.2022.06.003

- NOBLE https://doi.org/10.1016/S0140-6736(19)32972-1

- EXCEL 5 years https://www.nejm.org/doi/full/10.1056/nejmoa1909406

II. ASA for Primary Prevention

Daily Aspirin Challenged in Primary Stroke Prevention: ASPREE

https://www.medscape.com/viewarticle/994963

- ASPREE – All-cause mortality

- ASPREE (MACE and Bleeding) https://www.nejm.org/doi/full/10.1056/NEJMoa1805819

- ASPREE (disability) https://www.nejm.org/doi/full/10.1056/NEJMoa1800722

- JAMA Network Open Subanalysis https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2807630

III. Fish Oil

- OMEMI Substudy https://doi.org/10.1016/j.clnu.2023.07.002

- Gencer and colleagues Meta-analysis - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654

- OMEMI Main Trial https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.052209

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antiarrhythmic drugs in patients with CAD, observational studies, GLP-1 agonists, and the subcutaneous ICD are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. AAD in Patients with CAD

- The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease

https://doi.org/10.1016/j.jacep.2022.12.021

- Three Questions for Evidence-Based Cardiac Electrophysiology

https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381

- The Cardiac Arrhythmia Suppression Trial (CAST) https://www.nejm.org/doi/full/10.1056/nejm198908103210608

II. GLP-1 Agonists

Tirzepatide Powers Weight Loss in Two More Pivotal Trials https://www.medscape.com/viewarticle/994889

Semaglutide Use Surges in US Adults With Type 2 Diabetes https://www.medscape.com/viewarticle/994873

- Tirzepatide Once Weekly for the Treatment of Obesity

https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

https://doi.org/10.1016/S0140-6736(23)01200-X

III. S-ICD

S-ICD Shows Virtues, Limits in 'Real World' Postmarket Study https://www.medscape.com/viewarticle/994851

- Postapproval Study of a Subcutaneous Implantable Cardioverter-Defibrillator System https://doi.org/10.1016/j.jacc.2023.05.034

- Subcutaneous or Transvenous Defibrillator Therapy https://www.nejm.org/doi/full/10.1056/NEJMoa1915932

- Letter to the Editor https://www.nejm.org/doi/full/10.1056/NEJMc2034917

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Listener feedback, conduction system pacing, eating fish vs fish pills, exercise, and an RCT for diet are the topics discussed by John Mandrola,.MD, in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Listener Feedback Monitor HF and AHA

Jun 02, 2023 This Week in Cardiology Podcast

https://www.medscape.com/viewarticle/992678

- Link to the ACC Email -- https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2023/07/18/17/21/monitor-hf

- Tweet From Anthony Pearson

https://twitter.com/skepcard/status/1681288604990189574

II. Conduction System Pacing

- Clinical Outcomes in Conduction System Pacing Compared to Right Ventricular Pacing in Bradycardia https://doi.org/10.1016/j.jacep.2022.10.016

- Hormone Therapy To Prevent Disease and Prolong Life in Postmenopausal Women https://www.acpjournals.org/doi/abs/10.7326/0003-4819-117-12-1016

III. Fish Oil

Omega-3s and AF: No Added Risk From Eating Fish but High-Dose Supplement Questions Persist https://www.medscape.com/viewarticle/994559

- Omega-3 Fatty Acid Biomarkers and Incident Atrial Fibrillation

https://www.jacc.org/doi/full/10.1016/j.jacc.2023.05.024

- Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia https://www.nejm.org/doi/full/10.1056/nejmoa1812792

- Effect of Long-Term Marine ɷ-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-Analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.055654

IV. Exercise

Even Exercise by 'Weekend Warriors' Can Cut CV Risk

https://www.medscape.com/viewarticle/994617

- Accelerometer-Derived "Weekend Warrior" Physical Activity and Incident Cardiovascular Disease https://jamanetwork.com/journals/jama/article-abstract/2807286

V. Diet

Cognitive Benefit of Highly Touted MIND Diet Questioned

https://www.medscape.com/viewarticle/994550

- Trial of the MIND Diet for Prevention of Cognitive Decline in Older Persons

https://www.nejm.org/doi/full/10.1056/NEJMoa2302368

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

[email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carotid stents, the paclitaxel story now closed, inclisiran, DOAC failures, and primary vs secondary prevention are the topics John Mandrola, MD, covers in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Carotid Stenting CMS Proposal

Expanded Coverage of Carotid Stenting in CMS Draft Proposal

https://www.medscape.com/viewarticle/994315

No Added Benefit From Revascularization in Low-Risk CAS

https://www.medscape.com/viewarticle/992524

- Percutaneous Transluminal Angioplasty (PTA) of the Carotid Artery Concurrent with Stenting https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=311

- Second asymptomatic carotid surgery trial (ACST-2): a randomised comparison of carotid artery stenting versus carotid endarterectomy

https://doi.org/10.1016/S0140-6736(21)01910-3

- SPACE-2 https://journals.sagepub.com/doi/10.1177/1747493019833017

- Rationale, Design, and Implementation of Intensive Risk Factor Treatment in the CREST2 Trial 10.1161/STROKEAHA.120.030730

II. Paclitaxel

FDA: No Excess Mortality Risk From Paclitaxel Stents, Balloons for Peripheral Intervention https://www.medscape.com/viewarticle/994253

- FDA Statement https://www.fda.gov/medical-devices/letters-health-care-providers/update-paclitaxel-coated-devices-treat-peripheral-arterial-disease-unlikely-increase-risk-mortality?utm_medium=email&utm_source=govdelivery#_FDA_Actions

III. Inclisiran

FDA Expands Inclisiran Statin-Adjunct Indication to Include Primary Prevention https://www.medscape.com/viewarticle/994185

- ORION 10-11 Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol https://www.nejm.org/doi/10.1056/NEJMoa1912387

- Effect of inclisiran on lipids in primary prevention: the ORION-11 trial

https://doi.org/10.1093/eurheartj/ehac615

- Inclisiran and cardiovascular events: a patient-level analysis of phase III trials https://pubmed.ncbi.nlm.nih.gov/36331326/

IV. DOAC Failure

Association of Alternative Anticoagulation Strategies and Outcomes in Patients With Ischemic Stroke While Taking a Direct Oral Anticoagulant

https://doi.org/10.1212/WNL.0000000000207422

V. Primary or Secondary Prevention

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

European HTN Guidelines, vitamin D, bempedoic acid, and leadless pacing, with some critical appraisal techniques thrown in, are the topics John Mandrola, MD, tackles in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. European Hypertension Guidelines

New ESH Hypertension Guidelines Aim for Simplified Message

https://www.medscape.com/viewarticle/993913

- 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH)

https://pubmed.ncbi.nlm.nih.gov/37345492/

II. Vitamin D

CV Benefit From Vitamin-D Caps Hinted in Huge D-Health Trial

https://www.medscape.com/viewarticle/993996

- Vitamin D supplementation and major cardiovascular events: D-Health randomised controlled trial

https://www.bmj.com/content/381/bmj-2023-075230

- Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials

https://jamanetwork.com/journals/jamacardiology/fullarticle/2735646

III. Bempedoic Acid

'Striking' Benefit of Lipid Lowering in Primary Prevention

https://www.medscape.com/viewarticle/993666

- Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients

https://jamanetwork.com/journals/jama/fullarticle/2806646

- Bempedoic Acid for High-Risk Primary Prevention of Cardiovascular Disease

https://jamanetwork.com/journals/jama/fullarticle/2806647

- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients

https://www.nejm.org/doi/full/10.1056/NEJMoa2215024

IV. Leadless Pacing

FDA Approves First Leadless Dual-Chamber Pacing System

https://www.medscape.com/viewarticle/994033

- A Dual-Chamber Leadless Pacemaker

https://www.nejm.org/doi/full/10.1056/NEJMoa2300080

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

[email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Starting HF meds during hospitalization for HF, Impella, testosterone, and colchicine are the topics John Mandrola, MD, discusses in this week's podcast.

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I. Starting HF Meds During Hospitalization for HF

Starting Indicated Heart Failure Meds In-Hospital: Progress, Opportunities https://www.medscape.com/viewarticle/993539

- Opportunities and Achievement of Medication Initiation Among Inpatients With Heart Failure With Reduced Ejection Fraction https://www.jacc.org/doi/full/10.1016/j.jchf.2023.04.015

II. Impella

- Comparative Effectiveness of Percutaneous Microaxial Left Ventricular Assist Device vs Intra-Aortic Balloon Pump or No Mechanical Circulatory Support in Patients With Cardiogenic Shock

https://jamanetwork.com/journals/jamacardiology/fullarticle/2806562

- Evidence Generation for Novel Cardiovascular Devices—Putting the Horse Back in Front of the Cart

https://jamanetwork.com/journals/jamacardiology/fullarticle/2806565

III. Testosterone

Big Trial Reassures on Heart Safety of Testosterone in Men

https://www.medscape.com/viewarticle/993322

- Cardiovascular Safety of Testosterone-Replacement Therapy

https://www.nejm.org/doi/full/10.1056/NEJMoa2215025

IV. Colchicine for CV Disease

Low-Dose Colchicine Approved for CVD: Now What?

https://www.medscape.com/viewarticle/993578

- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction

https://www.nejm.org/doi/full/10.1056/nejmoa1912388

- Colchicine in Patients with Chronic Coronary Disease

https://www.nejm.org/doi/full/10.1056/nejmoa2021372

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact

[email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AF screening, BNP, a new SGLT2 inhibitor, a sky-is-blue study, and the UK Mini Mitral surgical trial are discussed in this week's podcast

This podcast is intended for healthcare professionals only.

To read a partial transcript or to comment, visit:

https://www.medscape.com/twic

I AF Screening

- Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064361

- Implantable loop recorder detection of atrial fibrillation to prevent stroke (The LOOP Study): a randomised controlled trial https://doi.org/10.1016/S0140-6736(21)01698-6

- Natural History of Subclinical Atrial Fibrillation Detected by Implanted Loop Recorders https://www.jacc.org/doi/full/10.1016/j.jacc.2019.09.050

- Prevalence and Prognostic Significance of Bradyarrhythmias in Patients Screened for Atrial Fibrillation vs Usual Care https://jamanetwork.com/journals/jamacardiology/fullarticle/2801362

- Stepwise mass screening for atrial fibrillation using N-terminal pro b-type natriuretic peptide: the STROKESTOP II study design https://doi.org/10.1093/europace/euw319

- Current misconception 3: that subgroup-specific trial mortality results often provide a good basis for individualising patient care https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068511/

II Frailty and GDMT of HFrEF

Frailty Linked to Lower Use of Guideline Treatments in HFrEF

https://www.medscape.com/viewarticle/993218

- Physical Frailty and Use of Guideline‐Recommended Drugs in Patients With Heart Failure and Reduced Ejection Fraction https://www.ahajournals.org/doi/10.1161/JAHA.122.026844

III Sotagliflozin

FDA Approves New Drug, Sotagliflozin, for Heart Failure

https://www.medscape.com/viewarticle/992518

- Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

https://www.nejm.org/doi/full/10.1056/NEJMoa2030186

- Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

https://www.nejm.org/doi/full/10.1056/NEJMoa2030183

IV Mini-Mitral

Support for Minimally Invasive Mitral Valve Repair: Mini Mitral Published

https://www.medscape.com/viewarticle/993191

- Minithoracotomy vs Conventional Sternotomy for Mitral Valve Repair

https://jamanetwork.com/journals/jama/article-abstract/2805908

You may also like:

Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine

https://www.medscape.com/features/public/machine

The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.

https://www.medscape.com/author/bob-harrington

Questions or feedback, please contact: [email protected]

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.